Pastore LLC successfully negotiated the separation of C-suite executive from a publically traded Boston based bio-tech company. Key issues involved the vesting of stock options and related plan documents, adherence to Rule 144 in the disposition of stock and the scope of non-competition agreements under Delaware law.
Tags: Firm News
Pastore Attorney Tyler W. Rutherford Quoted By Slate Concerning Sam Bankman-Fried’s Trial
Connecticut State Court Reduces Award by More than Half in Alternative Investment Hedge Fund Dispute